• 1
    Servat JJ, Mears KA, Black EH, Huang JJ. Biological agents for the treatment of uveitis. Exp Opin Biol Ther 2012; 12:311328.
  • 2
    Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant 2011; 20:514.
  • 3
    Zhang X, Jiao C, Zhao S. Role of mesenchymal stem cells in immunological rejection of organ transplantation. Stem Cell Rev 2009; 5:402409.
  • 4
    De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12:574591.
  • 5
    Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol 2012; 67:18.
  • 6
    Sun L, Wang D, Liang J et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010; 62:24672475.
  • 7
    Ciccocioppo R, Bernardo ME, Sgarella A et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60:788798.
  • 8
    Darlington PJ, Boivin MN, Bar-Or A. Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Exp Rev Neurother 2011; 11:12951303.
  • 9
    Liu Y, Mu R, Wang S et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010; 12:R210.
  • 10
    Xu J, Wang D, Liu D et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren's syndrome. Blood 2012; 120:31423151.
  • 11
    Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2:34.
  • 12
    Svobodova E, Krulova M, Zajicova A et al. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev 2012; 21:901910.
  • 13
    Mei SH, Haitsma JJ, Dos Santos CC et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010; 182:10471057.
  • 14
    Maltman DJ, Hardy SA, Przyborski SA. Role of mesenchymal stem cells in neurogenesis and nervous system repair. Neurochem Int 2011; 59:347356.
  • 15
    Zhang X, Ren X, Li G et al. Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity. Invest Ophthalmol Vis Sci 2011; 52:31433152.
  • 16
    Tasso R, Ilengo C, Quarto R, Cancedda R, Caspi RR, Pennesi G. Mesenchymal stem cells induce functionally active T regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53:786793.
  • 17
    Zhang X, Jiao C, Jia Z, Ren X, Li X, Zhao X. Investigation of the role of mesenchymal stem cells on keratoplasty rejection. Chin J Ophthalmol 2012; 48:733738.
  • 18
    Caspi RR. Experimental autoimmune uveoretinitis in the rat and mouse. Curr Protoc Immunol 2003; Chapter 15: Unit 15–16.
  • 19
    Shao H, Van Kaer L, Sun SL, Kaplan HJ, Sun D. Infiltration of the inflamed eye by NKT cells in a rat model of experimental autoimmune uveitis. J Autoimmun 2003; 21:3745.
  • 20
    Amadi-Obi A, Yu CR, Liu X et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13:711718.
  • 21
    Chi W, Yang P, Li B et al. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 2007; 119:12181224.
  • 22
    Chi W, Zhu X, Yang P et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 2008; 49:30583064.
  • 23
    Luger D, Silver PB, Tang J et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008; 205:799810.
  • 24
    Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 2010; 1183:211221.
  • 25
    Horai R, Caspi RR. Cytokines in autoimmune uveitis. J Interferon Cytokine Res 2011; 31:733744.
  • 26
    Ke Y, Jiang G, Sun D, Kaplan HJ, Shao H. Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis. Invest Ophthalmol Vis Sci 2008; 49:39994007.
  • 27
    Sun M, Yang P, Du L, Zhou H, Ren X, Kijlstra A. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2010; 51:383389.
  • 28
    Chen L, Yang P, Zhou H et al. Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt–Koyanagi–Harada syndrome. Invest Ophthalmol Vis Sci 2008; 49:34753482.
  • 29
    Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235238.
  • 30
    Zhou L, Lopes JE, Chong MM et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453:236240.
  • 31
    Korn T, Mitsdoerffer M, Croxford AL et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008; 105:1846018465.
  • 32
    Ferraro A, Socci C, Stabilini A et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011; 60:29032913.
  • 33
    Niu Q, Cai B, Huang ZC, Shi YY, Wang LL. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2012; 32:27312736.
  • 34
    Khoury SJ. Th17 and Treg balance in systemic sclerosis. Clin Immunol 2011; 139:231232.
  • 35
    Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Mesenchymal stem cells derived from Wharton's jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther 2013; 8:144155.